Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$813.14 +1.4%	$782.33	$510.05 ▼ $934.62	$50.57B	0.47	350,963 shs	314,403 shs
PFE Pfizer	$25.37 -0.7%	$26.73	$23.08 ▼ $28.75	$144.57B	0.34	41.34 million shs	30.92 million shs
TAK Takeda Pharmaceutical	$15.02 -1.1%	$17.18	$12.99 ▼ $18.90	$47.79B	-0.07	3.04 million shs	3.77 million shs
VTRS Viatris	$15.56 -0.8%	$14.97	$8.44 ▼ $17.53	$18.12B	0.9	10.72 million shs	6.97 million shs

Beginner's Guide To Retirement Stocks

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	-4.06%	-0.77%	+2.38%	+7.02%	+37.22%
PFE Pfizer	-0.27%	-1.20%	-3.02%	-3.99%	+8.97%
TAK Takeda Pharmaceutical	-0.01%	-4.27%	-8.61%	-16.61%	+0.85%
VTRS Viatris	-0.76%	-3.51%	+4.32%	+6.66%	+80.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$813.14 +1.4%	$782.33	$510.05 ▼ $934.62	$50.57B	0.47	350,963 shs	314,403 shs
PFE Pfizer	$25.37 -0.7%	$26.73	$23.08 ▼ $28.75	$144.57B	0.34	41.34 million shs	30.92 million shs
TAK Takeda Pharmaceutical	$15.02 -1.1%	$17.18	$12.99 ▼ $18.90	$47.79B	-0.07	3.04 million shs	3.77 million shs
VTRS Viatris	$15.56 -0.8%	$14.97	$8.44 ▼ $17.53	$18.12B	0.9	10.72 million shs	6.97 million shs

Beginner's Guide To Retirement Stocks

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	-4.06%	-0.77%	+2.38%	+7.02%	+37.22%
PFE Pfizer	-0.27%	-1.20%	-3.02%	-3.99%	+8.97%
TAK Takeda Pharmaceutical	-0.01%	-4.27%	-8.61%	-16.61%	+0.85%
VTRS Viatris	-0.76%	-3.51%	+4.32%	+6.66%	+80.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.92	Moderate Buy	$1,019.50	25.38% Upside
PFE Pfizer	2.20	Hold	$28.82	13.64% Upside
TAK Takeda Pharmaceutical	2.50	Moderate Buy	N/A	N/A
VTRS Viatris	2.38	Hold	$16.43	5.58% Upside

Current Analyst Ratings Breakdown

Latest VTRS, PFE, ARGX, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/1/2026	PFE Pfizer	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
6/1/2026	ARGX argenex	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,260.00 ➝ $1,291.00
5/27/2026	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$27.00
5/19/2026	VTRS Viatris	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$17.00 ➝ $22.00
5/14/2026	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$26.00
5/8/2026	VTRS Viatris	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
5/8/2026	VTRS Viatris	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $20.00
5/8/2026	ARGX argenex	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,120.00 ➝ $1,135.00
5/8/2026	ARGX argenex	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,247.00 ➝ $1,260.00
5/8/2026	VTRS Viatris	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$17.00 ➝ $18.00
5/6/2026	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)

(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	11.90	$20.75 per share	39.19	$118.34 per share	6.87
PFE Pfizer	$63.31B	2.28	$4.35 per share	5.83	$15.26 per share	1.66
TAK Takeda Pharmaceutical	$28.32B	1.69	$3.07 per share	4.89	$16.12 per share	0.93
VTRS Viatris	$14.30B	1.27	$7.27 per share	2.14	$12.77 per share	1.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$22.46	36.20	24.93	1.32	31.31%	33.28%	28.16%	7/23/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	19.36	8.87	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)
TAK Takeda Pharmaceutical	$1.27B	$0.39	38.50	8.53	N/A	4.31%	11.07%	5.49%	7/30/2026 (Estimated)
VTRS Viatris	-$3.51B	-$0.26	N/A	5.76	1.39	-2.04%	19.04%	7.62%	8/6/2026 (Estimated)

Latest VTRS, PFE, ARGX, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	ARGX argenex	$5.74	$5.52	-$0.22	$5.52	$1.44 billion	$1.31 billion
5/7/2026	Q1 2026	VTRS Viatris	$0.52	$0.59	+$0.07	$0.15	$3.36 billion	$3.52 billion
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
3/31/2026	Q1 2026	ARGX argenex	N/A	$5.52	N/A	$5.52	N/A	$1.31 billion
3/31/2026	Q4 2025	TAK Takeda Pharmaceutical	N/A	$0.5610	N/A	-$0.0483	N/A	$6.90 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.77%	-13.20%	131.30%	16 Years
TAK Takeda Pharmaceutical	$0.50	3.33%	-18.61%	128.21%	N/A
VTRS Viatris	$0.48	3.09%	N/A	N/A	N/A

Latest VTRS, PFE, ARGX, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/4/2026	VTRS Viatris	quarterly	$0.12	2.88%	5/22/2026	5/22/2026	6/17/2026
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.23	4.87
PFE Pfizer	0.67	1.25	0.94
TAK Takeda Pharmaceutical	0.56	1.27	0.70
VTRS Viatris	0.85	1.60	1.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
PFE Pfizer	68.36%
TAK Takeda Pharmaceutical	9.17%
VTRS Viatris	79.88%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
PFE Pfizer	0.62%
TAK Takeda Pharmaceutical	0.04%
VTRS Viatris	0.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.19 million	60.68 million	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
VTRS Viatris	30,000	1.16 billion	1.16 billion	Optionable

VTRS, PFE, ARGX, and TAK Headlines

Recent News About These Companies

Assessing Viatris (VTRS) Valuation After FDA Review Acceptance For Fast Acting Non Opioid Meloxicam

May 24, 2026 | finance.yahoo.com

Barclays Remains a Buy on Viatris (VTRS)

May 21, 2026 | theglobeandmail.com

Viatris (VTRS): Buy, sell, or hold post Q1 earnings?

May 20, 2026 | msn.com

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

May 19, 2026 | zacks.com

Here's Why Viatris (VTRS) is a Strong Momentum Stock

May 18, 2026 | zacks.com

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

May 18, 2026 | prnewswire.com

Deadline Alert: Viatris Inc. (VTRS) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

May 17, 2026 | businesswire.com

Does Strong Q1 Results And CFO Transition Change The Bull Case For Viatris (VTRS)?

May 17, 2026 | finance.yahoo.com

Viatris Shareholders Approve Directors, Pay and Auditor

May 15, 2026 | tipranks.com

Viatris (VTRS) price target increased by 10.47% to 17.48

May 14, 2026 | msn.com

Why Viatris (VTRS) is a top value stock for the long term

May 13, 2026 | msn.com

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

May 13, 2026 | zacks.com

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 12, 2026 | seekingalpha.com

Why Viatris (VTRS) is a Top Growth Stock for the Long-Term

May 12, 2026 | zacks.com

Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)

May 12, 2026 | seekingalpha.com

Viatris Inc. stock falls Monday, underperforms market

May 11, 2026 | marketwatch.com

Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating

May 11, 2026 | seekingalpha.com

Most healthcare companies report higher Y/Y EPS in strong earnings week

May 11, 2026 | seekingalpha.com

Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q1 2026 Update

May 8, 2026 | seekingalpha.com

VTRS Q1 deep dive: China strength, R&D pipeline, and execution drive outperformance

May 8, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTRS, PFE, ARGX, and TAK Company Descriptions

argenex NASDAQ:ARGX

$813.14 +10.97 (+1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$812.74 -0.39 (-0.05%)

As of 05:51 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Pfizer NYSE:PFE

$25.36 -0.19 (-0.72%)

Closing price 03:58 PM Eastern

Extended Trading

$25.38 +0.02 (+0.08%)

As of 05:51 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Takeda Pharmaceutical NYSE:TAK

$15.02 -0.17 (-1.09%)

Closing price 03:58 PM Eastern

Extended Trading

$15.28 +0.26 (+1.73%)

As of 05:12 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Viatris NASDAQ:VTRS

$15.56 -0.13 (-0.83%)

Closing price 04:00 PM Eastern

Extended Trading

$15.71 +0.15 (+0.99%)

As of 05:33 PM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTRS, PFE, ARGX, and TAK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTRS, PFE, ARGX, and TAK Earnings

Compare Dividends

Latest VTRS, PFE, ARGX, and TAK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTRS, PFE, ARGX, and TAK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTRS, PFE, ARGX, and TAK Company Descriptions

argenex NASDAQ:ARGX

Pfizer NYSE:PFE

Takeda Pharmaceutical NYSE:TAK

Viatris NASDAQ:VTRS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTRS, PFE, ARGX, and TAK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTRS, PFE, ARGX, and TAK Earnings

Compare Dividends

Latest VTRS, PFE, ARGX, and TAK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTRS, PFE, ARGX, and TAK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTRS, PFE, ARGX, and TAK Company Descriptions

argenex NASDAQ:ARGX

Pfizer NYSE:PFE

Takeda Pharmaceutical NYSE:TAK

Viatris NASDAQ:VTRS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools